Abstract:
In some embodiments, the present disclosure pertains to an injectable shear-thinning composition that comprises (a) one or more types of polymers, (b) one or more types of microparticles and (c) water. In some embodiments, the present disclosure pertains to a kit that comprises (a) one or more containers that contain an injectable shear-thinning composition that comprises one or more types of polymers, one or more types of microparticles and water and (b) a delivery device. In some embodiments, the present disclosure pertains to a medical procedure comprising administering to a subject an injectable shear-thinning composition that comprises one or more types of polymers, one or more types of microparticles and water.
Abstract:
A medical device include a polyurethane layer and a hydro-specific layer that is covalently bonded to the polyurethane layer. The polyurethane layer may include a plurality of monomer residues, at least some of which include pendent alkene groups. The hydro-specific layer may be a hydrophilic layer or a hydrophobic layer depending on the specific molecules used to form the hydro-specific layer. As an example, the hydro-specific layer may be covalently bonded to the polyurethane layer via a thiol-ene or alkene hydrothiolation reaction between the plurality of pendent alkene groups and a plurality of thiol-terminated hydro-specific molecules forming the hydro-specific layer.
Abstract:
According to some aspects, the present disclosure pertains to methods of forming dimethyl 5-tert-butylisophthalate which comprise comprising converting 5-tert-butylisophthalic acid into dimethyl 5-tert-butylisophthalate in synthesis procedures that comprises methanol and a dehydrating agent as chemical reagents. In other aspects, the present disclosure pertains to methods of forming 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene that comprise deprotonating 5-tert-butyl-1,3-bis(1-hydroxy-1-methylethyl)benzene with a Brønsted-Lowry superbase and methylating the deprotonated 5-tert-butyl-1,3-bis(1-hydroxy-1-methylethyl)benzene to form the 5-tert-butyl-1,3-bis(1-methoxy-1-methylethyl)benzene.
Abstract:
Aqueous liquid embolic compositions as well as method for making and using aqueous liquid embolic compositions are disclosed. An example aqueous liquid embolic composition may include a di-block or tri-block copolymer including a hydrophobic monomer block and a charged (polycationic or polyanionic) block. The charged (polycationic or polyanionic) block may include one or more anions. The aqueous liquid embolic composition may also include templating agent.
Abstract:
A chemotherapy agent comprising a chemotherapy group and a ligand secured to the chemotherapy group is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing chemotherapy agents from a patient is disclosed, the method comprising providing a chemotherapy agent containing a reactive group; providing a capture substrate in contact with a patient's bloodstream; administering the chemotherapy agent to the patient; and sequestering the chemotherapy agent on the capture substrate. A system for removing chemotherapy agents is also disclosed.
Abstract:
A lubricious coating for use on an implantable medical device includes a heterochelic component, a homotelechelic polymer and biocompatible initiator. Methods of forming such lubricious coatings are also provided.
Abstract:
The present disclosure pertains to injectable shear-thinning compositions that comprise (a) one or more types of fibrous proteins, (b) one or more types of silicate microparticles, (c) one or more types of radiopaque additives, (d) one or more types of cryoprotectants, and (e) water. Other aspects of the present disclosure pertain to kits that contains such compositions and medical procedures that comprise administering such compositions to a patient.
Abstract:
Embodiments herein relate to medical devices and methods for monitoring and/or treatment including the use of synthetic polymers exhibiting specific binding for compounds such as disease state markers or toxic substances. In an embodiment, a method of testing a patient for a disease state is included, the method can include withdrawing a fluid sample from the patient and contacting the fluid sample with an extracorporeal monitoring device. The extracorporeal monitoring device can include a microporous membrane. The microporous membrane can include a synthetic polymer, wherein the synthetic polymer exhibits binding specificity with a disease state marker. The method can further include evaluating the extracorporeal monitoring device for the presence of the disease state marker. Other embodiments are included herein.
Abstract:
In some aspects of the present invention, coatings are provided which provide lubricity as well as additional functionality. Further aspects of the invention pertain to medical devices having such coatings and methods of forming such coatings.